✦ LIBER ✦

Cost of Care with Everolimus Versus Axitinib for Second-Line Metastatic Renal Cell Carcinoma Patients in Canada

✍ Scribed by Perrin, A.; Chua, A.; Wang, X.; Hurry, M.

Book ID: 122289240
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 57 KB
Volume: 16
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.08.458

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of Everolimus for Sec

Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia

✍ Mihajlović, Jovan; Pechlivanoglou, Petros; Sabo, Ana; Tomić, Zdenko; Postma, Maa 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 284 KB

Phase II Randomized Trial Comparing Sequ

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

✍ Motzer, R. J.; Barrios, C. H.; Kim, T. M.; Falcon, S.; Cosgriff, T.; Harker, W. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 282 KB

PCN101 Cost Effectiveness of Everolimus

PCN101 Cost Effectiveness of Everolimus for Second Line Treatment of Metastatic Renal Cell Cancer in Serbia

✍ J. Mihajlović; P. Pechlivanoglou; A. Sabo; Z. Tomić; M.J. Postma 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB

Randomized Phase III Trial of Temsirolim

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

✍ Hutson, T. E.; Escudier, B.; Esteban, E.; Bjarnason, G. A.; Lim, H. Y.; Pittman, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 258 KB

PCN30 A COST—UTILITY ANALYSIS MODEL FOR

PCN30 A COST—UTILITY ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN MEXICO

✍ I Contreras-Hernandez; J Mould-Quevedo; G Salinas-Escudero; J Tapia-Valencia; G 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB